Yellow Fever Vaccine Market By Type of Vaccine (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine), By Application (Prevention of Yellow Fever, Travel Vaccination, Outbreak Control, Prevention of Yellow Fever in Special Populations), By Distribution Channel (Direct Sales, Government Procurement, Online Pharmacies, Retail Pharmacies, Wholesale Distribution), By End User (Hospitals, Clinics, Public Health Organizations, Travel Health Centers, Pharmacies, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Yellow Fever Vaccine market accounted for USD 1.44 Billion in 2024 and is expected to reach USD 2.92 Billion by 2035, growing at a CAGR of around 6.65% between 2025 and 2035. The Yellow Fever Vaccine market means the global market for developing, manufacturing, and selling vaccines that protect people against yellow fever an infectious disease spread through the bites of infected mosquitoes in tropical areas of Africa and South America.

As more governments and health organizations continue to roll out vaccination campaigns to control pandemics, there is heightened concern about disease prevention; new awareness of traveling to endemic areas adds up to the market. Pharmaceutical companies, research institutions, and non-profit organizations are among the most important stakeholders. The market is influenced by a variety of factors, including vaccine approval and other surveillance systems, technology, and illnesses such as Ebola. These include a shortage of vaccines, transportation difficulties due to cold storage requirements, and high costs in low-income countries.

Report Scope:

Market Dynamics

Increasing awareness about yellow fever prevention globally.

Rising global awareness of yellow fever prevention is regarded as one of the most significant growth contributors to the yellow fever vaccine market, helping public health by eradicating the deadly disease spread by mosquitos. Stakeholders collaborate to increase vaccine knowledge in the general public, guard against mosquitos, and identify early stages of the virus, all of which contribute to minimizing occurrence numbers. In this regard, governments and other relevant health organizations form key components to ensure that the vaccination endeavor achieves the intended goal.

In this regard, important global institutions such as the WHO have claimed significant improvement in vaccination campaigns in high-risk regions. These endeavors signal a need for international cooperation in the fine arts and a constant emphasis on the education of the public on health. Global awareness campaigns, on the other hand, raise public awareness, dispel myths, and make preventive measures more accessible, thereby reducing the vulnerability of vulnerable groups and improving overall health control systems.

Improved healthcare infrastructure in developing countries facilitating vaccine access.

Improved healthcare systems in underdeveloped countries are one of the primary factors that have enabled vaccination access, particularly for diseases like yellow fever. Optimized infrastructures, enhanced inventory management, and increased healthcare accessibility suggest that vaccines can reach such peripheral groups, indirectly contributing to the evolution of the Yellow Fever Vaccine Market.

Governments and global health institutes around the world, notably Gavi, the Vaccine Alliance, report progress toward expanding immunization coverage as a result of greater healthcare system investment. Not only does it make vaccinations more accessible, but it also helps individuals reestablish trust in public health efforts, increasing their likelihood of becoming vaccinated. The strengthening of infrastructures, therefore, results in the establishment of structures that curb negative health-related aspects such as diseases and, at the same time, improve the general health of the community.

Geopolitical instability affects vaccination programs in certain regions.

Political and social risks involve a high risk to the future performance of the Yellow Fever Vaccine Market, especially in areas experiencing conflict or political instabilities. Vaccination campaigns can be properly effective when they are supported with adequate infrastructure whereby healthcare delivery systems remain intact, but such environments are unstable. The factors that impede vaccines’ distribution and their administration include reach constraints, interrupted chains of distribution, and displacement of people.

Unfortunately, conflict-affected nations do not often have supportive governments, making it difficult for international agencies to introduce immunizations or respond to outbreaks in conflict zones. It increases the vulnerability of persons who have no protection against yellow fever. To address these issues, governments, global health organizations, humanitarian groups, and civil society must form strategic partnerships to make vaccines more accessible to conflict-affected communities.

Expanding vaccination campaigns in emerging markets.

Another powerful trend in developing countries remains the development of vaccination activities in the Yellow Fever Vaccine Market. Such areas generally define high-risk populations as such; the need for coverage following minimal or no vaccination in the past can be very compelling. With new funding sources and investments in the public health infrastructure, there is money and opportunities for vaccine manufacturers and healthcare providers to access these untapped markets. Local governments and health organizations supplement vaccinations to increase the impact of the immunization delivery. Furthermore, as residents in these locations get more health knowledge, the need for yellow fever immunizations increases. This expansion benefits many parts of society while also addressing business opportunities in vaccine manufacture and delivery.

Growing collaboration between governments and global health organizations.

The collapse between the governments and the global health organizations presents a great opportunity in the yellow fever vaccine market. Such partnerships normally promote resource focalization, transport optimization, and combined synchronization of strategies in combating yellow fever. Thus, governments can use the experience and the financial capacity of international organizations such as WHO and Gavi to ensure the organization of mass vaccination.

They also help with aspects like inadequate vaccines, increasing the cold chain, and getting access to remote locations. To continuously improve the delivery of immunization services, international collaboration also leads to heightened attempts to create novel ideas and strategies for additional vaccines and immunization programs. Along with the growth of the yellow fever vaccine market, this integration also helps improve healthcare systems around the world.

Industry Experts Opinion

"Yellow fever remains a significant global health threat, but the introduction of the vaccine has dramatically reduced its incidence. However, challenges in vaccine distribution, especially in remote and underserved areas, continue to hinder progress. Ensuring equitable access to the yellow fever vaccine is key in achieving global eradication efforts."

• Dr. Carlos Rivera, Epidemiologist and Public Health Researcher

Segment Analysis

Based on the type of vaccine, the yellow fever vaccine market is classified into live attenuated vaccines, inactivated vaccines, and recombinant vaccines. Currently, the highly desirable and substantial part of the global yellow fever vaccine market is inactivated vaccines. This vaccine type is preferred because it has the best safety record in protecting against yellow fever—a viral illness caused by infected mosquitoes. Inactivated vaccines like YF-Vax are currently used globally because they provide a long duration of immunity and low reactogenicity, appropriate for mass immunization campaigns.

Authorities and healthcare institutions choose inactivated vaccines for mass immunization since yellow fever remains an issue in many African and South American countries. First of all, inactivated vaccines are sometimes obligatory. To receive a visa for countries with yellow fever, which increases the demand for them on the market. Hence, its nonperishable nature and the fact that, in many cases, these products do not need to be stored in refrigeration further contribute to their popularity.

Based on the application, the vaccine market is classified into prevention of yellow fever, travel vaccination, outbreak control, and prevention of yellow fever in special populations. Thus, the provision of the yellow fever segment is the most important and noticeable. They bring this up because the main purpose of the vaccine is to prevent yellow fever, a fatal virus spread by mosquitoes. Yellow fever is spread throughout Sub-Saharan Africa and some parts of South America; hence, vaccination is the most effective strategy to prevent it.

The World Health Organization (WHO) relies heavily on mass vaccination. Efforts to control the disease, especially in countries where access to adequate treatment remains a luxury. Furthermore, there is a considerable global demand for yellow fever vaccines as the world seeks to eradicate the disease, which has increased the need for vaccines. This segment has developed a stronghold in the market because endemic areas have high vaccination rates, and regular immunization during outbreaks only strengthens this segment.

Regional Analysis

The North American yellow fever vaccine market is leading owing to factors such as the growing propensity to travel and the growing awareness of vaccine-preventable communicable diseases. These centers thus ensure availability and distribution of the vaccine is adopted in the region, especially in travel clinics as well as in healthcare centers. It is a mutual effort of both government and private society to ease the requirements of vaccination for travelers arriving from the affected regions by yellow fever. Similarly, the region’s regulatory authorities stress the necessity for clients who have left or arrived from the outbreak areas to be vaccinated.

Stakeholders based their surveys and educational campaigns on improving the knowledge of the population on vaccination. These clients include travelers who take preventive vaccines before they embark on their long journeys and tourists who may need emergency vaccines for their short trips. Measures to control yellow fever also apply pressure on people across the world to take vaccinations within the region. The level of demand for vaccines is anticipated to remain high because of steady epidemic uncertainties and the region’s focus on international public health. Likewise, North America has a robust pharmaceutical and biotech industry that supports progress in vaccinating populations and strengthening the region’s position again.

The yellow fever vaccine market has been growing rapidly in countries within the Asia Pacific region due to increased knowledge of yellow fever, international travel, and other factors. Authorities in the region have placed a high bar on travel vaccination, and this has boosted demand for the vaccine among citizens from the regions suffering from high endemic. Vaccination has been enhanced by many countries in the region to counter the outbreak of yellow fever in the region through adopting improved public health policies.

Also, due to increased tourism and increased economic integration in the region, the number of people from countries or regions with yellow fever is increasing, and travel to the region is increasing. They have also increased access to vaccines; the region's healthcare institutions have improved vaccine provision, particularly in cities and international airports. Regional alliances and international health institutes also help to expand the market's effective coverage. As the Americas develop and Hispanic populations rise, there is a greater need for preventative medicine and inoculation against diseases like yellow fever. Promoting vaccine access to increase availability and affordability is the primary element driving the region's market growth.

Competitive Landscape

The major market players in the Yellow Fever Vaccine Market are operating across both the global and regional markets. Market incumbents such as Sanofi Pasteur, GlaxoSmithKline, and Merck & Co. are the key players benefiting from high volume and affordable pricing and advanced distribution channels for their existing vaccine formulation. Advanced vaccine-creating technologies like mRNA and plant-based are being used commercially by new entrants like CureVac AG and bio, Inc. Bio-Mangino’s from Brazil, Institute Pasteur de Dakar from Senegal, and FSUE Chumakov from Russia are three manufacturing firms engaged in regional vaccine manufacture.

The development and manufacturing of second-generation vaccines, as well as other antiviral therapies, are associated with Bavarian Nordic and Valneva SE. Businesses like Biological E Limited and the Serum Institute of India are crucial in providing affordable vaccines to promote immunization worldwide. Joint ventures, collaboration, and government-sponsored initiatives to eradicate yellow fever in endemic areas further encourage competition.

Yellow Fever Vaccine Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In November 2024, Gavi released a Yellow Fever Vaccines Market Shaping Roadmap covering the period from 2024 to 2033. This roadmap outlines strategic objectives aimed at enhancing the availability and affordability of yellow fever vaccines, with a focus on at-risk countries in Africa and Latin America.
• In May 2024, BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.

Report Coverage:

By Type of Vaccine

• Live Attenuated Vaccine
• Inactivated Vaccine
• Recombinant Vaccine

By Application

• Prevention of Yellow Fever
• Travel Vaccination
• Outbreak Control
• Others

By Distribution Channel

• Direct Sales
• Government Procurement
• Online Pharmacies
• Retail Pharmacies
• Wholesale Distribution

By End User

• Hospitals
• Clinics
• Public Health Organizations
• Travel Health Centers
• Pharmacies
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Sanofi Pasteur
• Bio-Manguinhos
• FSUE Chumakov
• Institut Pasteur de Dakar
• iBio, Inc.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Biological E Limited
• Panacea Biotec
• Takeda Pharmaceutical Company Ltd
• Valneva SE
• Bavarian Nordic
• Hualan Biological Engineering Inc.
• Wockhardt Ltd.
• AbbVie Inc.
• Serum Institute of India Pvt. Ltd.
• CureVac AG

Frequently Asked Questions (FAQs)